Novo Nordisk A/S : Novo Nordisk A/S: People with type 2 diabetes achieve 6% weight loss with liraglutide 3 mg in phase 3a

 Novo Nordisk A/S : Novo Nordisk A/S: People with type 2 diabetes achieve 6%
         weight loss with liraglutide 3 mg in phase 3a obesity trial

Company announcement No 19 / 2013

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE
HUG#1685937